

STERLING BIOTECH LIMITED
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FIRST QUARTER ENDED 31ST MARCH, 2010

(Rs.in Lacs)

Sr. No.	Particulars	Quarter ended	Corresponding	For the Year
		31/03/2010	Quarter ended	Ended 31/12/2009
		Unaudited	Unaudited	Audited
1	Income			
	a) Net Sales/Income from Operations	38,278.25	34,957.49	143,817.29
	b) Other Operating Income	212.34	163.15	886.42
	c) Total	38,490.59	35,120.64	144,703.71
2	Expenditure			
	a) (Increase)/decrease in stock in trade and work in progress	(1,067.84)	(4,523.32)	(17,130.11)
	b) Consumption of raw materials	15,082.57	18,559.59	77,749.36
	c) Employees Cost	1,022.47	972.24	4,017.22
	d) Depreciation	3,223.85	3,006.93	12,304.21
	e) Other expenditure	7,365.63	6,792.54	28,629.32
	f) Total	25,626.68	24,807.98	105,570.00
3	Profit from Operations before Other Income and Interest (1-2)	12,863.91	10,312.66	39,133.71
4	Other Income	0.00	0.00	0.00
5	Profit before Interest (3+4)	12,863.91	10,312.66	39,133.71
6	Interest	5,527.54	2,994.20	14,943.77
7	Profit / (Loss) from Ordinary Activities before tax (5-6)	7,336.37	7,318.46	24,189.94
8	Tax expense			
	a) Current	1,210.00	850.00	3,500.00
	b) Deffered	1,200.00	1,400.00	3,350.00
	c) Fringe Benefit	0.00	12.50	12.50
	d) Total	2,410.00	2,262.50	6,862.50
9	Net Profit / (Loss) from Ordinary Activities after tax (7-8)	4,926.37	5,055.96	17,327.44
10	Extraordinary Items	(222.18)	(283.16)	6,205.12
11	Net Profit / (Loss) for the period (9-10)	4,704.19	4,772.80	23,532.56
12	Prior year adjustment	0.00	0.00	166.97
13	Profit available for appropriation	4,704.19	4,772.80	23,699.53
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,501.97	2,488.22	2,501.97
15	Reserves excluding Revaluation Reserves as per balance sheet.			204,530.55
16	Earnings Per Share (EPS)			
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.97	2.03	6.93
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.88	1.92	9.41
17	Public Shareholding			
	- Number of shares	133,666,531	132,291,603	133,666,531
	- Percentage of shareholding	53.42%	53.17%	53.42%
18	Promoters and Promoter Group Shareholding			
	a) Pledged/Encumbered			
	Number of shares	30,527,000	32,488,136	30,527,000
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	34.29%	36.49%	34.29%
	Percentage of shares (as a % of the total share capital of the Company)	12.20%	13.06%	12.20%
	b) Non-encumbered			
	Number of shares	58,507,694	56,546,558	58,507,694
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	65.71%	63.51%	65.71%
	Percentage of shares (as a % of the total share capital of the Company)	23.38%	22.73%	23.38%

STERLING BIOTECH LIMITED
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FIRST QUARTER ENDED 31ST MARCH, 2010

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 14th May, 2010.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 31st March, 2010
- 4 During the Quarter the Company has raised ECB Loan of USD 147.40 Million for implementation of Gelatin Manufacturing Facility in Special Economic Zone.
- 5 The number of investor complaints for the quarter ended on 31st March , 2010 were : Opening - NIL, Received - 4, Disposed off - 4, and Balance - NIL.
- 6 Previous period figures have been regrouped/reclassified, wherever necessary.

For and on Behalf of
STERLING BIOTECH LIMITED

Place : Mumbai
Date : 14th May, 2010.

Chetan J. Sandesara
Joint Managing Director